Steven Harr — Chief Financial Officer and Head of Corporate Development at Juno Therapeutics

Mr. Steven D. Harr, also known as Steve, M.D. has been the Chief Financial Officer and Head of Corporate Development at Juno Therapeutics Inc. since April 2014. Mr. Harr served as the Head of Investment Banking Group in the Biotechnology Sector at Morgan Stanley since May 2010. Dr. Harr served as an Equity Analyst at Morgan Stanley, Research Division. He joined Morgan Stanley in 2002 and covers biotechnology companies. Dr. Harr served as a Managing Director of Global Biotech Research at Morgan Stanley since December 15, 2006. He served as Morgan Stanley's lead Biotechnology Analyst and also as Co-Head of the Health Care Research Group. Dr. Harr covered biotech companies at Robertson Stephens. He served as Equity Analyst at Robertson Stephens, Inc., Research Division. He has consistently been ranked as a top analyst by polls such as Alpha, Greenwich and Institutional Investor. He has been an Independent Director of Loxo Oncology, Inc. since November 7, 2016. Dr. Harr was an internal medicine resident at the University of California, San Francisco and conducted research at Harvard Medical School. He holds an M.D. from the Johns Hopkins School of Medicine and a B.A. in Economics from Holy Cross College.